J Korean Fract Soc.  2010 Apr;23(2):167-171. 10.12671/jkfs.2010.23.2.167.

Results of Osteoporotic Treatment Drug after Periarticular Fracture of Hip

• Yim SJ
• Lee YK
• Kim CK
• Song HS
• Kang HK

• KMID: 1461538
• DOI: http://doi.org/10.12671/jkfs.2010.23.2.167

Abstract

PURPOSE
The Purpose of the study is to know patients' compliance of drug treatment of osteoporosis after operation of fracture and to compare of accompanying fractures between patients who diagnosed with osteoporosis itself and had the drug treatment of osteoporosis after surgery of periarticular fracture of hip.
MATERIALS AND METHODS
In experimental group, consecutive 60 patients who had fracture of femoral neck and trochanter. And in control group, 61 patients diagnosed osteoporosis with drug treatment within the same period in orthopedic department from July 2006 to July 2007. The average age is 73.8 (+/-6.7) year in experimental group, and 66.6 (+/-7.46) year in control group. Both groups had at least a year follow-up with drug treatment and had BMD again at least a year later.
RESULTS
BMD test in experimental group showed -3.05 (+/-1.35) preoperatively and -2.74 (+/-1.50) in last follow-up. BMD test in control group showed -3.55 (+/-0.52) in initial administration and -3.10 (+/-0.87) in last follow-up. The results showed a significant improvement in statistical analysis (p=0.0002, p<0.0001).
CONCLUSION
The compliance of drug treatment of osteoporosis after operation of periarticular fracture of hip is the same as in patients' diagnosed osteoporosis.

Keyword

Periarticular fracture of hip; Osteoporosis; Compliance

MeSH Terms

Compliance
Femur
Femur Neck
Follow-Up Studies
Hip
Humans
Orthopedics
Osteoporosis

Reference

1. Autier P, Haentjens P, Bentin J, et al. Belgian Hip Fracture Study Group. Costs induced by hip fractures: a prospective controlled study in Belgium. Osteoporos Int. 2000. 11:373–380.

2. Blouin J, Dragomir A, Ste-Marie LG, Fernandes JC, Perreault S. Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women. J Clin Endocrinol Metab. 2007. 92:887–894.

3. Boonen S, Autier P, Barette M, Vanderschueren D, Lips P, Haentjens P. Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study. Osteoporos Int. 2004. 15:87–94.

4. Brankin E, Walker M, Lynch N, Aspray T, Lis Y, Cowell W. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin. 2006. 22:1249–1256.

5. Bruyere O, Brandi ML, Burlet N, et al. Post-fracture management of patients with hip fracture: a perspective. Curr Med Res Opin. 2008. 24:2841–2851.

6. Cadarette SM, Katz JN, Brookhart MA, et al. Trends in drug prescribing for osteoporosis after hip fracture,1995-2004. J Rheumatol. 2008. 35:319–326.

7. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004. 15:1003–1008.

8. Colón-Emeric C, Kuchibhatla M, Pieper C, et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int. 2003. 14:879–883.

9. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ 3rd. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993. 137:1001–1005.

10. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005. 21:1453–1460.

11. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007. 18:1023–1031.

12. Haentjens P, Autier P, Barette M, Boonen S. Belgian Hip Fracture Study Group. The economic cost of hip fractures among elderly women. A one-year, prospective, observational cohort study with matched-pair analysis. Belgian Hip Fracture Study Group. J Bone Joint Surg Am. 2001. 83:493–500.

13. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006. 38:922–928.

14. Jung HJ, Choi JY, Shin HK, et al. Comparison between results of internal fixation and hemiarthroplasty in unstable intertrochanter fracture of osteoporotic bone. J Korean Fract Soc. 2007. 20:291–296.

15. Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N. Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J. 2008. 10:207–213.

16. Kim DH, Lee SH, Moon YL, Lee JY, Song KS. Treatment of senile osteoporotic intertrochanteric fracture using proximal femoral nail. J Korean Fract Soc. 2007. 20:215–221.

17. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000. 15:721–739.

18. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004. 48:271–287.

19. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2008. 19:511–517.

20. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006. 28:236–242.

21. Schürch MA, Rizzoli R, Mermillod B, Vasey H, Michel JP, Bonjour JP. A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res. 1996. 11:1935–1942.

22. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006. 81:1013–1022.

23. Trombetti A, Herrmann F, Hoffmeyer P, Schurch MA, Bonjour JP, Rizzoli R. Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int. 2002. 13:731–737.

24. van Helden S, Cals J, Kessels F, Brink P, Dinant GJ, Geusens P. Risk of new clinical fractures within 2 years following a fracture. Osteoporos Int. 2006. 17:348–354.

25. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int. 2007. 18:271–277.

26. Wolinsky FD, Fitzgerald JF, Stump TE. The effect of hip fracture on mortality, hospitalization, and functional status: a prospective study. Am J Public Health. 1997. 87:398–403.

27. Zethraeus N, Ben Sedrine W, Caulin F, et al. Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int. 2002. 13:841–857.